Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
-0.10 (-0.63%)
Apr 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.60 - 16.05
52 week 15.60 - 33.00
Open 15.90
Vol / Avg. 782,788.00/1.34M
Mkt cap 730.95M
P/E     -
Div/yield     -
EPS -0.76
Shares 46.41M
Beta 1.73
Inst. own 107%
Feb 9, 2017
Q4 2016 Acorda Therapeutics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -2.20% -6.85%
Operating margin 0.51% -6.92%
EBITD margin - -2.77%
Return on average assets -0.93% -2.90%
Return on average equity -1.86% -5.46%
Employees 597 -
CDP Score - -


420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
David Lawrence Chief Business Operations, Principal Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Burkhard Blank M.D. Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 44
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Catherine D. Strader Director
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 53
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters